VERICEL CORPORATION - COMMON STOCK

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

29 Dec 2022 12:45:00 By Nasdaq GlobeNewswire

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

10 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Vericel Reports Third Quarter 2022 Financial Results

09 Nov 2022 06:55:00 By Nasdaq GlobeNewswire

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

26 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

22 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Vericel Reports Second Quarter 2022 Financial Results

03 Aug 2022 06:55:00 By Nasdaq GlobeNewswire

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

21 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022

20 Jul 2022 07:30:01 By Nasdaq GlobeNewswire

Vericel Reports First Quarter 2022 Financial Results

04 May 2022 06:55:00 By Nasdaq GlobeNewswire

Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022

20 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022

15 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

01 Mar 2022 07:30:01 By Nasdaq GlobeNewswire

Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer

24 Feb 2022 15:45:00 By Nasdaq GlobeNewswire

Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance

24 Feb 2022 06:55:00 By Nasdaq GlobeNewswire

Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022

10 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth

02 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

04 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021

11 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Vericel Reports Third Quarter 2021 Financial Results

09 Nov 2021 06:40:00 By Nasdaq GlobeNewswire